Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical
Serious adverse events · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
1 finding from 1 review
- RR 1.34 [0.95, 1.89]2 studies · 350 participantsModerate